At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 198 enrolled
Drug / intervention
TVP-1012 1mgdrug
Likely dose
TVP-1012 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa
In Brief
A Phase 3 clinical trial evaluating TVP-1012 1mg for Parkinson's Disease. Completed, enrolled 198 participants across 56 sites.
Detailed Summary
The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartJul 2015
Primary CompletionMar 2017
TodayJul 2026
First PostedJan 14, 2015
Enrollment StartJul 10, 2015
Primary CompletionMar 14, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.5 years ago
Interventions
TVP-1012 1mgdrug
TVP-1012 1mg Tablets